Digital Transformation at Dr. Reddy's: MES, Leadership Buy-In, and AI as a Copilot for Root Cause Investigations
Dr. Reddy's Head of Digitization on the 15-year digital journey starting with MES, why leadership vision is the prerequisite for transformation, and how AI will act as an expert copilot for pharmaceutical investigations.
Vivek Gera Host
Co-founder · Leucine
Rajesh T
Head of Digitization & Excellence · Dr. Reddy's Laboratories
About this episode
Vivek Gera speaks with Rajesh T, Head of Digitization & Excellence at Dr. Reddy's Laboratories, about one of the most advanced digital transformation journeys in Indian pharmaceutical manufacturing — a program that began with MES implementation in 2010 and has built genuine digital maturity over 15 years. Rajesh argues that leadership vision is not just helpful but the prerequisite: without it, digitisation stalls at pilot projects. The conversation moves to the emerging role of AI in root cause investigations — where today a team of functional experts must sit together to correlate hundreds of variables — and Rajesh's conviction that AI will soon serve as a copilot: trained on thousands of pharmaceutical papers and guided by process knowledge to surface root causes that human analysis would miss or take months to identify.
Topics
Key takeaways
- Dr. Reddy's digital journey started with MES in 2010 — 15 years of continuous build-out, not a one-time project — and the maturity reached today is uncommon even globally, not just within India
- Leadership buy-in is not a nice-to-have: without a visionary belief in digital outcomes from the top, digitisation stalls at pilots; organisations that are blessed with that vision start early and compound the advantage
- Root cause investigation today requires a team of functional experts correlating hundreds of variables manually — a time-consuming process where the answer may not emerge even after weeks of analysis
- AI as a copilot for investigations: trained on thousands of pharmaceutical papers and scientific literature, it can bring pharmaceutical functional knowledge to data correlation and surface root causes that human linear analysis would miss
- The goal is not to replace the expert but to give the expert the best possible co-analyst — one that has read every relevant paper in the field and can apply that knowledge to your specific batch data
- The outcome of AI in investigations is not just faster root cause identification but better reports — with scientific justification embedded — rather than conclusions reached by exhaustion
Continue exploring
Powered by
Leucine MES
See how automated documentation eliminates the gaps that cause FDA 483 observations.
See Leucine MESSee how Leucine's AI-native platform is transforming pharmaceutical quality and manufacturing operations.
